This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel group, efficacy, and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with a DSM-IV-TR diagnosis of ADHD. Approximately 286 subjects will be randomized to either SPN-812 or matching placebo in a 1:1 ratio (143 subjects per arm). Following up to 4 weeks of screening, subjects will be treated with study medication (SM) for 6 weeks, then will either be enrolled in a separate OLE study or followed for an additional 1 week for safety. The total duration of the study is up to 10 weeks.

For this pilot study, children diagnosed with ADHD starting stimulant treatment for the first time, or have not received stimulant treatment in the prior 6 months, in rural settings will be the focus of efforts to improve time to optimal symptom control, in an effort to maximize the treatment benefit for the academic year. We anticipate that more frequent provision of information by families and teachers to medical providers, enabled by technology and remote monitoring tools, will encourage more rapid improvement in symptom burden. This would be achieved through timely, even weekly, titration of medication per the current treatment guidelines, which is only possible with symptom reports.

The goals of this pilot study are 2-fold:
• Evaluate caregiver and teacher utilization of the RAMP platform early in the treatment course of ADHD
• Evaluate provider utilization of the RAMP platform in everyday practice and management of children early in the treatment course of ADHD

The purpose of this research is to assess a group-based telehealth parenting program for child ages 2-6 years old with a neurodevelopmental diagnosis and behavior problems. Families will complete an online intake assessment, 6 group-based telehealth PCIT sessions, and an online post intervention assessment. Families will be compensated for their time.